Date Filed | Type | Description |
04/29/2021 |
GN
| Emergent BioSolutions Reports Financial Results for First Quarter 2021 |
04/21/2021 |
GN
| Statement on Issuance of Form FDA 483 at Emergent Bayview Facility |
04/02/2021 |
GN
| Emergent BioSolutions Announces Topline Data from NIAID Phase 3 ITAC Trial (INSIGHT-013) Evaluating Immunoglobulins as a Treatment for Hospitalized Patients with COVID-19 |
03/01/2021 |
GN
| Emergent BioSolutions to Participate in Investor Conferences |
02/18/2021 |
GN
| Emergent BioSolutions Reports Financial Results for Fourth Quarter and Full Year 2020 |
02/04/2021 |
GN
| Emergent BioSolutions to Release Fourth Quarter and Full Year 2020 Financial Results and Conduct a Conference Call on February 18, 2021 |
01/10/2021 |
GN
| Emergent BioSolutions Announces 2021 Financial Guidance, Provides Preliminary 2020 Results |
01/04/2021 |
GN
| Emergent BioSolutions to Participate in Investor Conferences |
12/29/2020 |
GN
| Emergent BioSolutions and Mount Sinai Health System Announce Initiation of DOD-Funded Clinical Program to Evaluate COVID-19 Human Hyperimmune Globulin (COVID-HIG) Product Candidate for Prophylaxis |
10/15/2020 |
GN
| Emergent BioSolutions to Release Third Quarter 2020 Financial Results and Conduct Conference Call on November 5, 2020 |
10/08/2020 |
GN
| Emergent BioSolutions' COVID-19 Human Immune Globulin Product Candidate to be Included in NIH-Sponsored Phase 3 Clinical Trial of Hyperimmune Intravenous Immunoglobulin to Treat COVID-19 |
08/31/2020 |
GN
| Emergent BioSolutions Teams Up with Boston Red Sox, Cincinnati Reds, Philadelphia Phillies, and MAPDA to Highlight Importance of Overdose Reversal Medicines on International Overdose Awareness Day |
08/26/2020 |
GN
| Emergent BioSolutions Announces Appointment of Marvin White to the Company's Board of Directors |
08/18/2020 |
GN
| Emergent BioSolutions to Participate in Virtual Investor Conferences |
08/17/2020 |
GN
| UPDATE -- Emergent BioSolutions Announces FDA Approval of NARCAN® (naloxone HCl) Nasal Spray Shelf Life Extension to 36 Months |
08/17/2020 |
GN
| Emergent BioSolutions Announces FDA Approval of NARCAN® (naloxone HCl) Nasal Spray Shelf Life Extension to 36 Months |
08/07/2020 |
GN
| Emergent BioSolutions Announces Successful Completion of Offering of 3.875% Senior Unsecured Notes Due 2028 |
08/04/2020 |
GN
| Emergent BioSolutions Announces Upsize and Pricing of $450 Million of 3.875% Senior Unsecured Notes Due 2028 |
07/30/2020 |
GN
| Emergent BioSolutions Reports Financial Results for Second Quarter and Six Months Ended June 30, 2020 and Revises Upward Full Year 2020 Guidance |
07/27/2020 |
GN
| Emergent BioSolutions Signs Agreement with AstraZeneca to Expand Manufacturing for COVID-19 Vaccine Candidate |
07/21/2020 |
GN
| Emergent BioSolutions Inc. to be Added to the S&P MidCap 400 Index |
07/16/2020 |
GN
| Emergent BioSolutions to Release Second Quarter 2020 Financial Results and Conduct Conference Call on July 30, 2020 |
07/08/2020 |
GN
| Mount Sinai Health System, Emergent BioSolutions, and ImmunoTek Bio Centers Form Collaboration to Develop Emergent's COVID-19 Hyperimmune Globulin (COVID-HIG) Product Candidate with U.S. Department of Defense Funding |
06/18/2020 |
GN
| Emergent BioSolutions to Invest $75 Million in Canton Site and Expand Viral Vector and Gene Therapy Capability |
06/16/2020 |
GN
| Emergent BioSolutions to Participate in Virtual Investor Conferences |
06/11/2020 |
GN
| Emergent BioSolutions Signs Agreement to be U.S. Manufacturing Partner for AstraZeneca's COVID-19 Vaccine Candidate |
06/05/2020 |
GN
| Emergent BioSolutions Statement on U.S. District Court Decision |
06/01/2020 |
GN
| Emergent BioSolutions Joins U.S. Government's Warp Speed Program in Landmark Public-Private CDMO Partnership for COVID-19 Vaccine Development and Manufacturing |
05/12/2020 |
GN
| Emergent BioSolutions to Participate in Virtual Investor Conferences |
05/07/2020 |
GN
| Emergent BioSolutions to Hold Virtual Annual Meeting of Stockholders on Thursday, May 21, 2020 at 9:00am EDT |
04/30/2020 |
GN
| Emergent BioSolutions Reports Financial Results for First Quarter 2020 |
04/23/2020 |
GN
| Emergent BioSolutions Signs Agreement to be U.S. Manufacturing Partner for Johnson & Johnson's Lead Vaccine Candidate for COVID-19 |
04/21/2020 |
GN
| Emergent BioSolutions Appoints Dr. Karen L. Smith as Chief Medical Officer |
04/16/2020 |
GN
| Emergent BioSolutions to Release First Quarter 2020 Financial Results and Conduct Conference Call on April 30, 2020 |
|